证券代码：600129 证券简称：太极集团 公告编号：2023-42 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙）， 不涉及会计师事务所的变更。 一、拟聘任的会计师事务所的基本情况 | （一）机构信息 | | --- | | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 18 | 年 | 月 | 日 | 组织形式 | | | 特殊普通合伙 | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | | | | | 128 | 号 | | | | 首席合伙人 | 胡少先 上年末合伙人数量 | | | | | | | 225 人 | | | 上年末执业人 | 注册会计师 | | | | | | | 2,064 | 人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师 | | | | | | | 780 | 人 | | 2022 年（经审 | 业务收入总额 38.63 | | | | | | 亿 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-41 重庆太极实业（集团）股份有限公司 关于使用部分闲置募集资金暂时用于补充 流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 为提高募集资金使用效率，重庆太极实业（集团）股份有限公司 （以下简称：公司或太极集团）拟使用不超过 25,000 万元的闲置募 集资金补充流动资金，使用期限为自董事会审议通过之日起不超过 12 个月，到期及时归还到募集资金专用账户。 2023 年 8 月 23 日，公司第十届董事会第十五次会议、第十届监 事会第十二次会议审议通过了《关于使用部分闲置募集资金暂时用于 补充流动资金的议案》，现将相关事宜公告如下： 一、募集资金基本情况 三、前次使用部分闲置募集资金暂时用于补充流动资金到期归还 的情况 2022 年 10 月 26 日，公司第十届董事会第十次会议《关于使用 部分闲置募集资金暂时用于补充流动资金的议案》，同意公司使用不 超过 41,000 万元闲置募集资金暂时用于补充流动资金，使用期限为 自董事会审 ...

证券代码：600129 证券简称：太极集团 公告编号：2023-37 特此公告。 重庆太极实业（集团）股份有限公司 2023 年 8 月 18 日 2022 年 10 月 26 日，重庆太极实业（集团）股份有限公司（以 下简称：公司）第十届董事会第十次会议审议通过了《关于使用部分 闲置募集资金暂时用于补充流动资金的议案》，同意公司使用不超过 41,000 万元闲置募集资金暂时用于补充流动资金，使用期限为自董 事会审议通过之日起不超过 12 个月。 2023 年 1 月 9 日，公司将上述用于补充流动资金的 16,000 万元 归还至募集资金专项账户。 具体内容详见公司刊登于《中国证券报》《上海证券报》《证券 时报》《证券日报》及上海证券交易所网站（www.sse.com.cn）的公 告（公告编号：2022-51 2022-53 2023-01） 2023 年 8 月 17 日，公司归还用于暂时补充流动资金的闲置募集 资金 25,000 万元至公司募集资金专用账户，本次归还的募集资金使 用期限未超过 12 个月。截止本公告披露日，公司用于暂时补充流动 资金的闲置募集资金 41,000 万元已全部归还。公司已将归 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 4,427,245,377.14, representing a 25.27% increase compared to CNY 3,534,245,541.53 in the same period last year[4] - Net profit attributable to shareholders was CNY 234,964,030.36, a significant increase of 991.16% from CNY 21,533,423.14 in the previous year[4] - Basic and diluted earnings per share reached CNY 0.42, up 950.00% from CNY 0.04 in the same period last year[4] - The weighted average return on equity increased by 6.61 percentage points to 7.40% compared to 0.79% in the previous year[4] - Total operating revenue for Q1 2023 reached RMB 4,427,245,377.14, an increase of 25.3% compared to RMB 3,534,245,541.53 in Q1 2022[14] - Total operating costs for Q1 2023 were RMB 4,128,707,044.10, up from RMB 3,435,516,881.19 in Q1 2022, reflecting a growth of 20.2%[14] - Net profit for Q1 2023 reached ¥236,597,822.43, a significant increase from ¥19,362,960.82 in Q1 2022, representing a growth of approximately 1,122%[15] - Revenue from sales of goods and services amounted to ¥3,589,221,222.00, up from ¥2,970,296,954.17 in the same quarter last year, indicating a year-over-year increase of about 21%[17] - Total comprehensive income for Q1 2023 was ¥236,579,781.70, compared to ¥19,355,029.97 in Q1 2022, showing an increase of approximately 1,223%[16] - Operating profit for the quarter was ¥283,030,582.49, a significant rise from ¥23,339,076.77 in the previous year, representing an increase of about 1,115%[15] Cash Flow and Assets - Cash flow from operating activities generated a net amount of CNY 238,520,917.50, a 227.59% increase from CNY 72,810,990.11 in the previous year[4] - Current assets totaled RMB 7,971,061,940.39 as of March 31, 2023, down from RMB 8,339,052,767.30 at the end of 2022, a decrease of 4.4%[11] - Cash and cash equivalents decreased to RMB 1,758,767,672.48 from RMB 2,374,432,028.57, a decline of 26.0%[11] - Accounts receivable increased to RMB 2,637,162,023.74, up 31.8% from RMB 2,001,104,912.10 in the previous year[11] - Total assets at the end of the reporting period were CNY 14,639,006,510.61, a decrease of 1.73% from CNY 14,896,326,064.64 at the end of the previous year[4] - Total liabilities decreased to RMB 11,476,764,124.54 from RMB 11,969,326,021.98, a reduction of 4.1%[13] - Non-current assets increased to RMB 6,667,944,570.22 from RMB 6,557,273,297.34, reflecting a growth of 1.7%[12] - The company reported a decrease in investment income, with a loss of ¥890,359.92 compared to a gain of ¥2,340,601.22 in Q1 2022[15] - The net cash flow from investing activities was -162,163,428.82, compared to -114,616,895.69 in the previous year, indicating a significant increase in cash outflow[18] - The total cash and cash equivalents at the end of the period amounted to 1,354,013,486.49, an increase from 809,347,247.66 year-over-year[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,702, with the largest shareholder holding 27.62% of the shares[8] - Shareholder equity attributable to shareholders increased by 7.64% to CNY 3,290,527,503.99 from CNY 3,056,913,540.43 at the end of the previous year[4] Expenses and Investments - Research and development expenses increased to ¥38,026,695.20, compared to ¥19,324,301.49 in Q1 2022, reflecting a growth of approximately 97%[15] - Tax expenses for the quarter were ¥47,735,484.37, compared to ¥5,516,338.30 in Q1 2022, indicating an increase of approximately 767%[15] - The company reported cash outflows for the acquisition of fixed assets and intangible assets totaling 183,126,713.50, compared to 145,099,458.79 in the previous year, marking an increase of approximately 26.2%[18] Future Plans - The company plans to focus on market expansion and new product development in the upcoming quarters[10]

Financial Performance - The company's net profit attributable to shareholders for 2022 was CNY 349,702,842.36, a significant recovery from a net loss of CNY 523,174,260.71 in 2021[3]. - Total operating revenue for 2022 reached CNY 14,050,659,364.39, representing a year-on-year increase of 15.65% compared to CNY 12,149,432,719.04 in 2021[15]. - The net cash flow from operating activities for 2022 was CNY 1,800,768,932.71, an increase of 222.25% from CNY 558,812,795.72 in 2021[15]. - The company's total assets as of the end of 2022 were CNY 14,707,197,661.95, up 11.67% from CNY 13,170,023,352.56 at the end of 2021[15]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,063,772,315.86, reflecting a 12.35% increase from CNY 2,727,075,186.70 at the end of 2021[15]. - The company reported a net profit excluding non-recurring gains and losses of CNY 366,629,474.69 for 2022, compared to a loss of CNY 697,094,865.85 in 2021[15]. - Basic and diluted earnings per share were 0.63 yuan, compared to a loss of 0.94 yuan per share in 2021[16]. - The weighted average return on equity increased to 12.08%, up 29.62 percentage points from -17.54% in 2021[16]. - The company achieved a revenue of 14.051 billion yuan in the reporting period, a 15.65% increase from 12.149 billion yuan in the same period last year[38]. Operational Highlights - The company will not distribute profits for 2022 due to significant operational funding needs following its turnaround[3]. - The company has maintained a standard unqualified audit report from Tianjian Accounting Firm for the fiscal year[2]. - The company achieved a 22.5% year-on-year increase in pharmaceutical industrial output value, reaching a historical high[29]. - The company launched a digital traceability platform for traditional Chinese medicine to enhance quality control throughout the supply chain[28]. - The company established a commercial management framework "1+2+3" to enhance operational efficiency and resource integration[26]. - The company expanded its traditional Chinese medicine planting bases to 150,000 acres, adding 24,000 acres during the reporting period[27]. - The company has implemented a centralized procurement model to reduce costs while ensuring quality, with strict supplier qualification and quality analysis systems[34]. Research and Development - The total R&D expenditure amounted to CNY 161,055,946.44, which is 1.15% of total revenue, with capitalized R&D accounting for 34.32% of the total[50]. - The company has over 80 ongoing research projects, with nearly 20 new projects initiated during the reporting period[70]. - The company is focusing on the development of innovative drugs and traditional Chinese medicine formulations to address various medical conditions[70]. - The company has completed the clinical trial for the innovative traditional Chinese medicine Danqi Tongmai tablets for cardiovascular diseases and is advancing several other key projects[30]. - The company is actively promoting the integration of production, learning, and research with top research institutions to build a collaborative innovation network[30]. Market Strategy - The company plans to continue focusing on high-quality development and operational efficiency improvements in the upcoming fiscal year[23]. - The company aims for a revenue growth of over 20% year-on-year in 2023, with a target of achieving 30% growth in the pharmaceutical sector[98]. - The company is expanding its market presence in key regions, targeting nine major markets including Sichuan, Chongqing, Beijing, and Guangdong[98]. - The company is committed to improving the competitiveness of its traditional Chinese medicine products, particularly in the OTC market[99]. - The company is leveraging the aging population and rising living standards to drive demand for pharmaceutical products[96]. Corporate Governance - The board of directors consists of 15 members, with a majority being external directors, ensuring independent oversight and governance[105]. - The company emphasizes investor relations management, ensuring timely and fair information disclosure to all shareholders[106]. - The company has maintained a consistent board structure with terms for directors and supervisors set to end in May 2024[110]. - The company has not reported any significant changes in its major shareholders or related party transactions that could affect its independence[108]. - The company is focused on maintaining its operational independence from its controlling shareholders and has not identified any major competitive threats from related entities[108]. Environmental Responsibility - The company has invested a total of 21.994 million yuan in social responsibility projects, benefiting 100,000 people[165]. - The company has implemented carbon reduction measures, achieving a reduction of 5,551 tons of CO2 equivalent emissions[162]. - The company has established a total of 1 national-level green factory and 3 provincial-level green factories[160]. - The company has constructed a new wastewater treatment plant with a capacity of 5,000 tons per day at the Fuling Pharmaceutical Factory[161]. - The company has established emergency response plans for environmental incidents, with specific registration numbers for each subsidiary[156]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 1.32 billion[113]. - New product launches are expected to contribute an additional 200 million in revenue, with a focus on innovative healthcare solutions[113]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 100 million allocated for strategic acquisitions[113]. - The company plans to increase production capacity by 30% at its digital oral formulation workshop in Taiji Pharmaceutical City[101]. - The company is committed to strengthening its supply chain and increasing negotiation power for bulk purchasing to improve net profit margins[100].

证券代码：600129 证券简称：太极集团 公司编号：2023-25 重庆太极实业（集团）股份有限公司 关于召开公司 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示: 重庆太极实业（集团）股份有限公司（以下简称：公司）已于2023 年3月31日发布公司2022年度报告，为便于广大投资者更全面深入地 了解公司2022年度经营成果、财务状况，公司计划于2023年4月12日 （星期三）下午14:00-15:00举行2022年度业绩说明会，就投资者关 心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对2022年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 ●会议召开时间：2023年4月12日（星期三）下午14:00-15:00 ●会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ● ...